# Diabetes Research Hub — Monitor Report
**Run date:** 2026-10-04 (automated review; no existing files modified)

**Headline:** Nothing urgent. The 2026-10-03 pipeline ran on schedule and produced no real clinical-trial changes. [Certain: programmatic diff of the 10-02 and 10-03 snapshots.] Two structural problems keep recurring: the tracker is 79 days stale, and the gap-score ranking is saturated.

## File System Status
| File | Last modified | Status |
|---|---|---|
| hub_monitor_report.md | 2026-10-03 | Fresh (1 day) |
| clinical_trials_latest.json | 2026-10-03 | Fresh; byte-identical to snapshot_2026-10-03 |
| pubmed_recent_latest.json | 2026-10-03 | Fresh; identical to snapshot_2026-10-03 |
| literature_gap_data.json / literature_gap_report.md | 2026-10-03 | Fresh |
| Diabetes_Research_Tracker.xlsx | 2026-07-17 | **STALE: 79 days** |
| No 2026-10-04 snapshots yet | — | Expected; pipeline runs ~05:00–10:00 local |

hub_monitor flags 874 live result files older than 14 days. Most are audit and cache JSONs, so not all need a refresh.

## Clinical Trial Changes (10-02 → 10-03)
- 906 trials. New 0, removed 0, status changes 0, new results 0. [Certain]
- The only differences are 96 `intervention_types` strings whose element order changed. Script artifact, not data. Fix: sort the list in `baseline_clinical_trials.py`.
- 159 Phase 3 trials; 63 Phase 3 RECRUITING. 10 of those are from Vertex, Lilly or Novo:
  - Vertex: NCT06832410, NCT04786262 (VX-880 / zimislecel).
  - Lilly: NCT07222137, NCT07222332 (baricitinib T1D); NCT07613307 (orforglipron); NCT06739122 (dulaglutide pediatric).
  - Novo: NCT07797335 (zenagamtide, AMBITION 7); NCT07564414, NCT07282613, NCT07817251 (CagriSema).
- Most recent registry results posted: NCT06109311 (Lilly orforglipron, 2026-10-01). It is still carried as BRONZE until tied to a verified paper. The other recent postings (Duke, Astellas, UMass, Kansas, UCSF) are lower priority.

## PubMed Highlights (157 papers, 17 domains, 30-day lookback)
- 17 new papers and 16 dropped since 10-02. 28 papers appear in multiple domains.
- New cross-domain paper: **42824926**, renal tissue microbiota and metabolite profiling in diabetic kidney disease (Biomarker × Microbiome × Multi-Omics). It is the best fit for the Tier 1 Multi-Omics area. Evidence level: unreviewed (title/abstract only).
- Carry-over highest-value items (from the 10-03 report, not re-verified): 42815506 (Lancet, orforglipron CV safety vs glargine); 42720752 and 42767751 (teplizumab).
- New key-therapy papers are low-evidence reviews: 42760621 (orforglipron review) and 42783450 (incretin therapy and hematological effects, retatrutide-tagged).
- Key-therapy 30-day counts: zimislecel 0, orforglipron 14, retatrutide 11, CagriSema 3, teplizumab 7, baricitinib 2, finerenone 39.
- Caveat: `domain_retmax` is 10, so per-domain volume trends cannot be measured.

## Gap Analysis Summary
Top 5 (22 of 435 pairs tie at 100.0, so the order is tie order, not signal):
1. Beta Cell Regen × Health Equity (0 joint)
2. Insulin Resistance × Islet Transplant (1)
3. Islet Transplant × GWAS/Polygenic (0)
4. Islet Transplant × Personalized Nutrition (0)
5. Islet Transplant × Drug Repurposing (0)

- Islet Transplant has only 255 publications and LADA 616. Small domains plus keyword mismatch likely inflate these scores. [Likely]
- Literature Synthesis & Gap Analysis is itself a Tier 1 area (RESEARCH_DOCTRINE.md line 28). A saturated score is therefore a method defect, not just noise.
- To upgrade this from Likely to Certain, recompute with observed/expected ratios and confidence intervals, plus a synonym-expanded query for Islet Transplant and LADA.

## Breaking News (web, last ~7 days)
Both searches returned low-quality or irrelevant results (fundraiser pages, conference PDFs, recaps from 2025 and mid-2026). Nothing verifiable surfaced on Phase 3 readouts or FDA actions. [Guessing: snippets only.] A WDAM/WDTV video dated 2026-08-30 mentions an FDA "new use of popular diabetes drug", but it is outside the 7-day window and unverified. No escalation.

## Recommended Actions
1. Update Diabetes_Research_Tracker.xlsx (79 days stale), starting with NCT06109311.
2. Read the abstract of PMID 42824926 and decide whether it feeds the multi-omics Tier 1 work. Verify the PMID before any claim.
3. Fix the gap scoring: replace the saturated score with an observed/expected ratio and CI. Then re-run `python project1_literature_gap_analysis.py`.
4. Sort `intervention_types` in `baseline_clinical_trials.py` to stop the false-positive diffs.
5. Raise `domain_retmax` in `baseline_pubmed_alerts.py` if you want real volume trends.
6. Manually check NCT05757713 (Sanofi teplizumab pediatric); it was not confirmed in the registry pull.
